Lifecore Biomedical (LFCR) to Release Quarterly Earnings on Thursday

Key Points

• Lifecore Biomedical is set to announce its Q4 2025 earnings on August 7th, with analysts predicting a loss of ($0.03) per share and revenue of $35.36 million.
• The company's stock is currently trading at $7.24, having increased by 3.5%, with a recent 12-month low of $3.68 and a high of $8.85.
• In related news, major shareholder Aron R. English sold over 150,000 shares, reducing their ownership by 36.28%, while institutional investors now hold 83.36% of Lifecore's stock.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) is anticipated to announce its Q4 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $35.36 million for the quarter.

Lifecore Biomedical Stock Up 3.5%

LFCR stock traded up $0.25 during trading on Monday, reaching $7.24. 47,060 shares of the company traded hands, compared to its average volume of 224,646. Lifecore Biomedical has a 12 month low of $3.68 and a 12 month high of $8.85. The business has a 50 day simple moving average of $7.40 and a 200 day simple moving average of $6.68. The company has a market capitalization of $267.91 million, a price-to-earnings ratio of -5.00 and a beta of 0.65. The company has a debt-to-equity ratio of 66.36, a quick ratio of 1.59 and a current ratio of 2.71.

Analyst Upgrades and Downgrades

Separately, William Blair assumed coverage on Lifecore Biomedical in a report on Wednesday, May 21st. They issued an "outperform" rating for the company.

Insider Activity at Lifecore Biomedical

In related news, major shareholder Aron R. English sold 150,419 shares of Lifecore Biomedical stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $7.12, for a total transaction of $1,070,983.28. Following the completion of the transaction, the insider directly owned 264,180 shares in the company, valued at approximately $1,880,961.60. This trade represents a 36.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 1,460,639 shares of company stock worth $9,650,266 over the last three months. Insiders own 32.20% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lifecore Biomedical stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) by 14.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,785 shares of the company's stock after buying an additional 1,886 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Lifecore Biomedical were worth $104,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 83.36% of the company's stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.